US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

15.79

+0.52003.41%

Post-market: 16.020.2300+1.46%16:26 EDT

Volume:1.04M

Turnover:16.19M

Market Cap:2.02B

PE:-4.82

High:16.01

Open:15.12

Low:14.93

Close:15.27

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:0.34

T/O Rate:1.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.44

PE(LYR):-3.17

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Generate Biomedicines Initiated at Overweight by Piper Sandler

Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS

Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating

MT Newswires Live

Generate Biomedicines Initiated at Buy by Guggenheim

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target

MT Newswires Live

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Generate Biomedicines CEO Michael Nally Acquires Common Shares

Generate Biomedicines Director Jane L Mendillo Acquires Common Shares

Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares

Generate Biomedicines Adopts Amended and Restated Bylaws

Opening Day: Generate Biomedicines makes public debut

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/GENB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":15.79,"timestamp":1788292800000,"preClose":15.27,"halted":0,"volume":1037106,"hourTrading":{"tag":"盘后","latestPrice":16.02,"preClose":15.79,"latestTime":"16:26 EDT","volume":6343,"amount":100159.230302,"timestamp":1788294378071,"change":0.23,"changeRate":0.014566,"amplitude":0.018683},"delay":0,"changeRate":0.03405370006548786,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Post-Mkt","change":0.52,"latestTime":"09-01 16:29:01 EDT","open":15.12,"high":16.01,"low":14.93,"amount":16194705.76521,"amplitude":0.070727,"askPrice":16.02,"askSize":2000,"bidPrice":15.5,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":15.27,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":15.27,"latestTime":"09:20 EDT","volume":8136,"amount":123796.96919999999,"timestamp":1788268834987,"change":-0.27,"changeRate":-0.017682,"amplitude":0.045318},"postHourTrading":{"tag":"盘后","latestPrice":16.02,"preClose":15.79,"latestTime":"16:26 EDT","volume":6343,"amount":100159.230302,"timestamp":1788294378071,"change":0.23,"changeRate":0.014566,"amplitude":0.018683},"volumeRatio":0.338708},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.338708,"shares":128192484,"dividePrice":0,"high":16.01,"amplitude":0.070727,"preClose":15.27,"low":14.93,"week52Low":11,"pbRate":"4.44","psRate":"76.43","week52High":22.6699,"institutionHeld":0,"latestPrice":15.79,"committee":-0.998002,"eps":-3.27625,"divideRate":0,"volume":1037106,"delay":0,"ttmEps":-3.27625,"open":15.12,"prevYearClose":16,"prevWeekClose":15.33,"prevMonthClose":15.27,"prevQuarterClose":16.87,"fiveDayClose":20.38,"twentyDayClose":14.28,"sixtyDayClose":12.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782532800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-08-31","current":-4.700496,"percent":0.309524,"low":-11.002825,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"high":-6.883628,"avg":-8.152533,"sd":0.750188,"marketCap":1967642843},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-08-31","current":-8.276414,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"marketCap":1967642843}],"updateTime":1788274201609},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DK","CVI","BZAI","FIG","AIR","AARD","AFG","INSM","FANG","AMZP","AMZD","BXP","CVX","FIGG","AVTX","CDE","EVGO","GLW","ESE","HD","BPH","USAW.SI","DG","APEI","BRZE","GENB","HAL","ABSI","AZYY","BP","CEGX","CEG","AMZU","BCAX","BTM","ARE","KBH","DINO","ADUS","AMZN","BAM","MTDR","ACAD","ELVN","BWXT","CNM","AVAH","FRPT","CALM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621706775","title":"Generate Biomedicines Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706775?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:02","pubTimestamp":1774357320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:02 ET (13:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621205062","title":"Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621205062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621205062?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:44","pubTimestamp":1774356269,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061288","title":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061288?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353049,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061159","title":"Generate Biomedicines Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061159?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:46","pubTimestamp":1774352760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:46 ET (11:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063010","title":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347431,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068889","title":"Generate Biomedicines initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:15","pubTimestamp":1774343742,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050714","title":"Generate Biomedicines initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050714?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342831,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $24 price target The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575470","title":"Generate Biomedicines initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:35","pubTimestamp":1774341311,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $26 price target The company integrates generative AI models...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0251142724.SGD","LU2750360641.GBP","IE0002270589.USD","LU2237443382.USD","LU2237443978.SGD","BK4551","BK4528","GSX","LU1868836757.USD","BK4550","LU2237443622.USD","LU2265009873.SGD","IE00BSNM7G36.USD","LU2237443895.HKD","BK4139","LU1791807156.HKD","LU1868836591.USD","LU0345770308.USD","LU0061475181.USD","BK4516","LU2471134796.USD","LU2237438978.USD","IE0004091025.USD","LU1868836914.USD","IE00B19Z3581.USD","LU0251131958.USD","LU2237443465.HKD","IE00B19Z3B42.SGD","LU1668664300.SGD","AI","LU0106831901.USD","LU1868837300.USD","BK4543","BK4588","LU0742534661.SGD","LU1894683348.USD","BK4127","LU2471134523.USD","BK4585","BK4504","LU0345770993.USD","LU2471134952.CNY","BK4023","LU2750360997.AUD","AIYY","IE0034235188.USD","BK4587","IE0004086264.USD","GENB","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621000051","title":"Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2621000051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621000051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621012051","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco","url":"https://stock-news.laohu8.com/highlight/detail?id=2621012051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621012051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:39","pubTimestamp":1774337945,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, SunocoMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apogee","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4N40C0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMYY","CCL","T","BK4165","STRO","APA","SPG","INSM","SMCI","KRYS","LW","VZ","ADM","LU0496365809.HKD","BK4504","ACDC","SMCC","MKC","XNCR","CXW","CF","BK4189","FRT","RL","GENB","KMI","SMCY","DAR","VTRS","RLMD","TSN","SMCX","NCNO","ECL","NYT","LU0354030511.USD","BG","APGE","LGND","DXCM","BK4515","LU0690374961.EUR","BRX","WEC","SRZN","PFE","SUN","REG","SMCZ","SMCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617538936","title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617538936","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617538936?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:56","pubTimestamp":1772834209,"startTime":"0","endTime":"0","summary":"Michael Nally, chief executive officer and director of Generate Biomedicines Inc., reported acquiring 20,000 shares of the company’s common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL7rR47K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616636213","title":"Generate Biomedicines Director Jane L Mendillo Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616636213","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616636213?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:48","pubTimestamp":1772491686,"startTime":"0","endTime":"0","summary":"Jane L Mendillo, a director of Generate Biomedicines Inc., reported an acquisition of 1,500 common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3FZcFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616362984","title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616362984","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616362984?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:43","pubTimestamp":1772491420,"startTime":"0","endTime":"0","summary":"Noubar Afeyan, a director and 10% owner of Generate Biomedicines Inc., reported the acquisition of common shares. The filing also lists reporting beneficial owners including Flagship VentureLabs VI LLC, Flagship Pioneering Fund VI, L.P., Flagship Pioneering Fund VII, L.P., Nutritional Health LTP Fund, L.P., and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8qZfyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616364281","title":"Generate Biomedicines Adopts Amended and Restated Bylaws","url":"https://stock-news.laohu8.com/highlight/detail?id=2616364281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616364281?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:22","pubTimestamp":1772490160,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Inc. announced amended and restated bylaws that took effect with the effectiveness of its IPO registration statement. The changes establish procedures for stockholders to take formal actions at stockholder meetings, add an advance notice process for stockholder proposals and director nominations at annual meetings, and update the bylaws to align with the company’s amended and restated certificate of incorporation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8gq2lY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616735468","title":"Opening Day: Generate Biomedicines makes public debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2616735468","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616735468?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:30","pubTimestamp":1772469040,"startTime":"0","endTime":"0","summary":"Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","AIYY","BK4551","BK4587","BK4543","BK4023","BK4528","BK4588","GENB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}